Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis
…, B Sipos, SA Hahn, S Klein-Scory… - Proceedings of the …, 2000 - National Acad Sciences
Smad4/DPC4 (deleted in pancreatic carcinoma, locus 4) is a tumor suppressor gene lost at
high frequency in cancers of the pancreas and other gastrointestinal organs. Smad4 …
high frequency in cancers of the pancreas and other gastrointestinal organs. Smad4 …
MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL
…, H Zöllner, J Munding, S Klein-Scory… - …, 2012 - academic.oup.com
MicroRNAs (miRNAs) are small non-coding RNAs that are involved in different biological
processes by suppressing target gene expression. Altered expression of miR-30a-5p has been …
processes by suppressing target gene expression. Altered expression of miR-30a-5p has been …
Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma
…, HE Meyer, W Uhl, S Klein‐Scory… - … journal of cancer, 2013 - Wiley Online Library
Improved non‐invasive strategies for early cancer detection are urgently needed to reduce
morbidity and mortality. Non‐coding RNAs, such as microRNAs and small nucleolar RNAs, …
morbidity and mortality. Non‐coding RNAs, such as microRNAs and small nucleolar RNAs, …
Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells
KA Adamczyk, S Klein-Scory, MM Tehrani, U Warnken… - Life sciences, 2011 - Elsevier
AIMS: Members of the epidermal growth factor receptor (EGFR) family represent validated
targets for anti-cancer therapy and EGFR inhibitors have also shown efficacy in pancreatic …
targets for anti-cancer therapy and EGFR inhibitors have also shown efficacy in pancreatic …
[HTML][HTML] A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding
…, E Sadeqzadeh, JV Weiß, MM Tehrani, S Klein-Scory… - PloS one, 2014 - journals.plos.org
In pancreatic cancer, there is a clear unmet need to identify new serum markers for either early
diagnosis, therapeutic stratification or patient monitoring. Proteomic analysis of tumor cell …
diagnosis, therapeutic stratification or patient monitoring. Proteomic analysis of tumor cell …
[HTML][HTML] Evolution of RAS mutational status in liquid biopsies during first-line chemotherapy for metastatic colorectal cancer
S Klein-Scory, I Wahner, M Maslova… - Frontiers in …, 2020 - frontiersin.org
Treatment options for patients with metastatic colorectal cancer (mCRC) are limited. This
particularly affects the largest group of patients with RAS mutations, who are considered …
particularly affects the largest group of patients with RAS mutations, who are considered …
[HTML][HTML] New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions
S Klein-Scory, MM Tehrani, C Eilert-Micus… - Proteome science, 2014 - Springer
Background Pancreatic cancer development is associated with characteristic alterations like
desmoplastic reaction and immune escape which are mediated by the cell-cell …
desmoplastic reaction and immune escape which are mediated by the cell-cell …
Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer
Smad4 is a tumor suppressor gene primarily involved in carcinogenesis of the pancreas
and colon. The functional inactivation of Smad4 is a late step genetically. In pancreatic …
and colon. The functional inactivation of Smad4 is a late step genetically. In pancreatic …
[HTML][HTML] Significance of liquid biopsy for monitoring and therapy decision of colorectal cancer
S Klein-Scory, M Maslova, M Pohl, C Eilert-Micus… - Translational …, 2018 - Elsevier
PURPOSE: Despite therapeutic improvements, all patients with nonresectable metastatic
colorectal cancer (mCRC) acquire resistance to treatment probably due to the growth of …
colorectal cancer (mCRC) acquire resistance to treatment probably due to the growth of …
[HTML][HTML] Digital-droplet PCR for quantification of CD19-directed CAR T-cells
T Mika, A Maghnouj, S Klein-Scory… - Frontiers in Molecular …, 2020 - frontiersin.org
CD19-directed CAR-T-cells (CD19-CAR) have demonstrated remarkable clinical results in
patients suffering from refractory or relapsed lymphoma and acute lymphoblastic leukemia. In …
patients suffering from refractory or relapsed lymphoma and acute lymphoblastic leukemia. In …